|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
Message: The present review proposes a novel theory; unlike other hypoglycemic agents or diuretics, SGLT2 inhibitor could protect DKD from failing by improving latent renal congestion even without symptomatic HF.
|
31291624 |
2019 |
|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
These include: (i) updating the CKD concept, shifting the emphasis to the identification, risk stratification and care of early CKD and redefining the concept of aging-associated 'physiological' decline of renal function; (ii) advances in the characterization of aetiological factors, including challenging the concept of hypertensive nephropathy, the better definition of the genetic contribution to CKD progression, assessing the role of the liquid biopsy in aetiological diagnosis and characterizing the role of drugs that may be applied to the earliest stages of injury, such as SGLT2 inhibitors in diabetic kidney disease (DKD); (iii) embracing the complexity of CKD as a network disease and (iv) exploring ways to optimize implementation of existing knowledge.
|
28667063 |
2017 |
|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
The recent finding that inhibition of proximal tubule (PT) glucose transport (via SGLT2) is nephro-protective in diabetic patients is discussed in relation to the tubule's potential role in DN.
|
28840540 |
2017 |
|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
The effects of dapagliflozin (Dapa) on the activation of the Nlrp3 inflammasome and the combined effect of SGLT2 and DPP4 on T2DM-induced inflammasome activation and progression of DN have not been previously studied.
|
29508169 |
2018 |
|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
SGLT-2 Inhibition: A Potential New Treatment for Diabetic Kidney Disease?
|
28743130 |
2017 |
|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prevention of progression of diabetic nephropathy by the SGLT2 inhibitor ipragliflozin in uninephrectomized type 2 diabetic mice.
|
29702076 |
2018 |
|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
Blockade of glucose reabsorption in tubular cells by SGLT2 inhibitor might exert beneficial effects on tubulointerstitial damage in diabetic nephropathy.
|
26158396 |
2016 |
|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
Empagliflozin, a sodium-glucose cotransporter-2 (SGLT-2) inhibitor, possesses verified anti-inflammatory and anti-oxidative stress effects against diabetic nephropathy.
|
31168342 |
2019 |
|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, the treatment of diabetes mellitus using SGLT2 inhibitors could be one of the effective approach for the management of diabetic-associated kidney disease like DN.
|
28759755 |
2017 |
|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the EMPA-REG OUTCOME trial, SGLT2 inhibition with empagliflozin reduced the primary outcome of major adverse cardiovascular events (MACE), while also reducing mortality, hospitalization for heart failure, and progression of diabetic kidney disease.
|
29735306 |
2018 |
|
Diabetic Nephropathy
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, SGLT2 mRNA expression was lower in DKD compared with HC or GN and inversely related to interstitial fibrosis.
|
31545924 |
2019 |
|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
SGLT2 inhibitors display renoprotective effects in diabetic kidney disease, which creates a rationale for testing the therapeutic potential of this drug class in nondiabetic chronic kidney disease.
|
30089717 |
2018 |
|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recently, sodium-glucose co-transporter 2 (SGLT2) inhibitors have been demonstrated to reduce cardiovascular complications and slow diabetic kidney disease progression in patients with type 2 diabetes.
|
31198226 |
2019 |
|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
There may be a growing role for sodium-glucose co-transporter 2 (SGLT-2) inhibitors in diabetic renal disease and for glucagon-like peptide (GLP)-1 therapy in renal and liver disease (nonalcoholic steatohepatitis).
|
30742277 |
2019 |
|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
This Perspective summarizes proposed mechanisms of action for SGLT2 inhibitors, integrates these data with results of recent cardiovascular outcomes trials, and discusses clinical applications for patients with DKD.
|
30665953 |
2019 |
|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
Based on these findings, we hypothesized that SGLT2 plays a pivotal role in the development of diabetic nephropathy and retinopathy and that SGLT2 inhibitors may directly protect against these complications.
|
28535208 |
2017 |
|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
Significant increases occurred in the uptake of new diabetic medications; DPP-4 inhibitors and SGLT-2 inhibitors and in the utilization of ACEIs and ARBs compared to the findings reported in other studies with increased complexity in the treatment of patients with diabetic nephropathy.
|
28295491 |
2017 |
|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, the pathophysiological crosstalk of SGLT2 with AGEs-RAGE axis and its role in diabetic nephropathy remains unknown.
|
23508966 |
2013 |
|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
SGLT2 inhibition to address the unmet needs in diabetic nephropathy.
|
30997935 |
2019 |
|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
The second aim of this study was to determine the potential mechanisms of beneficial effects of SGLT2 inhibition in the progression of diabetic renal disease.
|
28196866 |
2017 |
|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
Simultaneous use of SGLT-2 inhibitors and renin-angiotensin-aldosterone system (RAAS) blockers are novel strategies to slow the progression of DKD via reducing inflammatory and fibrotic markers induced by hyperglycaemia more than either drug alone.
|
28511711 |
2017 |
|
Diabetic Nephropathy
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Even with recent studies employing SGLT2 inhibitors demonstrating protection against cardiovascular and kidney diseases, kidney function continues to decline in people with established diabetic kidney disease (DKD).
|
31693730 |
2019 |
|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the kidney, SGLT-2 inhibitors reduce hyperfiltration, a precipitant of diabetic nephropathy.
|
28444472 |
2017 |
|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
Results of ongoing clinical trials in patients with DKD are eagerly awaited to expand knowledge of how SGLT2 inhibitors might be used for prevention and treatment.
|
29866460 |
2018 |
|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hypoxia-inducible factor-1α is the therapeutic target of the SGLT2 inhibitor for diabetic nephropathy.
|
31611596 |
2019 |